- Home
- CHRS vs BCOV Comparison
CHRS vs BCOV Comparison
Compare CHRS & BCOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- BCOV
- Stock Information
- Founded
- CHRS 2010
- BCOV 2004
- Country
- CHRS United States
- BCOV United States
- Employees
- CHRS N/A
- BCOV N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- BCOV EDP Services
- Sector
- CHRS Health Care
- BCOV Technology
- Exchange
- CHRS Nasdaq
- BCOV Nasdaq
- Market Cap
- CHRS 191.3M
- BCOV 195.6M
- IPO Year
- CHRS 2014
- BCOV 2012
- Fundamental
- Price
- CHRS $1.24
- BCOV $4.43
- Analyst Decision
- CHRS Strong Buy
- BCOV Buy
- Analyst Count
- CHRS 4
- BCOV 2
- Target Price
- CHRS $5.38
- BCOV $3.98
- AVG Volume (30 Days)
- CHRS 2.0M
- BCOV 473.4K
- Earning Date
- CHRS 03-12-2025
- BCOV 02-20-2025
- Dividend Yield
- CHRS N/A
- BCOV N/A
- EPS Growth
- CHRS N/A
- BCOV N/A
- EPS
- CHRS N/A
- BCOV N/A
- Revenue
- CHRS $304,340,000.00
- BCOV $199,834,000.00
- Revenue This Year
- CHRS $2.47
- BCOV $0.45
- Revenue Next Year
- CHRS N/A
- BCOV $1.54
- P/E Ratio
- CHRS N/A
- BCOV N/A
- Revenue Growth
- CHRS 44.19
- BCOV N/A
- 52 Week Low
- CHRS $0.66
- BCOV $1.55
- 52 Week High
- CHRS $2.87
- BCOV $4.44
- Technical
- Relative Strength Index (RSI)
- CHRS 37.51
- BCOV 78.12
- Support Level
- CHRS $1.38
- BCOV $4.32
- Resistance Level
- CHRS $1.45
- BCOV $4.44
- Average True Range (ATR)
- CHRS 0.13
- BCOV 0.02
- MACD
- CHRS -0.04
- BCOV -0.03
- Stochastic Oscillator
- CHRS 4.50
- BCOV 90.91
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About BCOV Brightcove Inc.
Brightcove Inc is a provider of cloud-based streaming technology and services. The firm targets its solutions at media companies, broadcasters, digital publishers, sports and entertainment companies, fashion and hospitality brands, faith-based institutions, retail and e-commerce businesses, and technology organizations, as well as government agencies, educational institutions and non-profit organizations. Brightcove Video Cloud is the firm's flagship product, enabling customers to publish and distribute video to Internet-connected devices. Video Cloud generates a portion of the firm's revenue through a subscription-based software-as-a-service model. Other products include Zencoder, a cloud-based video encoding service. It generates a large majority of its revenue in North America and Asia.